Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study - PubMed (original) (raw)

. 2014 Mar 10;32(8):768-73.

doi: 10.1200/JCO.2013.50.4357. Epub 2014 Jan 13.

Mattia Boeri, Marta Rossi, Carla Verri, Paola Suatoni, Francesca Bravi, Luca Roz, Davide Conte, Michela Grassi, Nicola Sverzellati, Alfonso Marchiano, Eva Negri, Carlo La Vecchia, Ugo Pastorino

Affiliations

Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study

Gabriella Sozzi et al. J Clin Oncol. 2014.

Erratum in

Abstract

Purpose: Recent screening trial results indicate that low-dose computed tomography (LDCT) reduces lung cancer mortality in high-risk patients. However, high false-positive rates, costs, and potential harms highlight the need for complementary biomarkers. The diagnostic performance of a noninvasive plasma microRNA signature classifier (MSC) was retrospectively evaluated in samples prospectively collected from smokers within the randomized Multicenter Italian Lung Detection (MILD) trial.

Patients and methods: Plasma samples from 939 participants, including 69 patients with lung cancer and 870 disease-free individuals (n = 652, LDCT arm; n = 287, observation arm) were analyzed by using a quantitative reverse transcriptase polymerase chain reaction-based assay for MSC. Diagnostic performance of MSC was evaluated in a blinded validation study that used prespecified risk groups.

Results: The diagnostic performance of MSC for lung cancer detection was 87% for sensitivity and 81% for specificity across both arms, and 88% and 80%, respectively, in the LDCT arm. For all patients, MSC had a negative predictive value of 99% and 99.86% for detection and death as a result of disease, respectively. LDCT had sensitivity of 79% and specificity of 81% with a false-positive rate of 19.4%. Diagnostic performance of MSC was confirmed by time dependency analysis. Combination of both MSC and LDCT resulted in a five-fold reduction of LDCT false-positive rate to 3.7%. MSC risk groups were significantly associated with survival (χ1(2) = 49.53; P < .001).

Conclusion: This large validation study indicates that MSC has predictive, diagnostic, and prognostic value and could reduce the false-positive rate of LDCT, thus improving the efficacy of lung cancer screening.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.

Fig 1.

CONSORT diagram (The Multicentric Italian Lung Detection [MILD] study, 2005 to 2012). LDCT, low-dose computed tomography.

Fig 2.

Fig 2.

Three-year survival from date of blood sample collection according to microRNA (miRNA) signature classifier among all patients (Multicentric Italian Lung Detection [MILD] study, 2005 to 2012). (*) No death occurred due to other causes in lung cancer–free participants.

Comment in

References

    1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: Three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180:445–453. - PubMed
    1. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease: The randomised Danish Lung Cancer Screening Trial—Status after five annual screening rounds with low-dose CT. Thorax. 2012;67:296–301. - PubMed
    1. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21:308–315. - PubMed
    1. National Lung Screening Trial Research Team. Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources